Vivani Medical Mergers and Acquisitions Presentation Deck

Combined Company Pipeline If Approved, Vivani Candidates will Compete in Markets with Large Potential Feasibility Pre-Clinical Clinical Nano Precision Medical SSMP Indication Human Type II Diabetes Feline Pre- Diabetes & Diabetes NASH (Non- Alcoholic Steatohepatitis) Human Obesity Profound Blindness NPM-119 exenatide OKV-119** exenatide NPM-159*** proprietary compound NPM-139*** proprietary compound ORION visual prosthesis Market Size* >$20B >$500M >$18B >$19B >$1B * Estimated Market Sizes where Vivani candidates would compete, if approved; Does not represent future sales or revenue estimates of Vivani candidates ** In Partnership with Okava Pharmaceuticals, Inc. *** Feasibility in progress with a non-exenatide compound in collaboration with a major pharma company

View entire presentation